Homolak, J. & Kodvanj, I. (2020). Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. International Journal of Antimicrobial Agents, 56. (2). doi: 10.1016/j.ijantimicag.2020.106044
Homolak, Jan and Ivan Kodvanj. "Widely available lysosome targeting agents should be considered as potential therapy for COVID-19." International Journal of Antimicrobial Agents, vol. 56, no. 2, 2020. https://doi.org/10.1016/j.ijantimicag.2020.106044
Homolak, Jan and Ivan Kodvanj. "Widely available lysosome targeting agents should be considered as potential therapy for COVID-19." International Journal of Antimicrobial Agents 56, no. 2 (2020). https://doi.org/10.1016/j.ijantimicag.2020.106044
Homolak, J. and Kodvanj, I. (2020) 'Widely available lysosome targeting agents should be considered as potential therapy for COVID-19', International Journal of Antimicrobial Agents, 56(2). doi: 10.1016/j.ijantimicag.2020.106044
Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. International Journal of Antimicrobial Agents [Internet]. 2020 August [cited 2024 August 30];56(2). doi: 10.1016/j.ijantimicag.2020.106044
J. Homolak and I. Kodvanj, "Widely available lysosome targeting agents should be considered as potential therapy for COVID-19", International Journal of Antimicrobial Agents, vol. 56, no. 2, August 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:050587. [Accessed: 30 August 2024]